Latest Boardroom Shifts News

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Elixinol Wellness reported a 9.5% revenue increase in Q4 FY25 alongside a 30% reduction in operating costs, setting a clear path to profitability under fresh executive leadership.

ASX Limited reported robust half-year results with an 11.2% rise in operating revenue and a steady net profit, while advancing its technology upgrade and responding to regulatory scrutiny.

ASX Limited has posted a solid 8.3% increase in net profit for the half-year ending December 2025, while announcing a reduced dividend payout and the planned departure of its CEO. The company is navigating regulatory scrutiny and investing heavily in technology upgrades.

Lendlease CEO Tony Lombardo will step down in August 2026, marking a leadership change after five years at the helm and a significant strategic reset. The Board has begun the search for his successor as the company prepares for its next growth phase.

AMP Limited reported a 20.8% rise in underlying net profit after tax for 2025, driven by growth in wealth platforms and investments, alongside a planned CEO transition and pending class action settlements.

Novo Resources has significantly increased the Exploration Target at its Belltopper Gold Project in Victoria, with multiple high-grade prospects across its Australian portfolio and drilling programs planned throughout 2026.

Tamboran Resources Corporation reported a 26% reduction in half-year losses as it progresses key natural gas projects in Australia’s Beetaloo Basin and prepares for a major acquisition of Falcon Oil & Gas Ltd.

Tamboran Resources has marked significant milestones in the Beetaloo Basin with successful drilling, major capital raises, and a new CEO appointment, targeting first gas sales in Q3 2026.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

EROAD Limited’s CEO Mark Heine has announced his resignation effective June 2026, concluding an 11-year tenure marked by significant company growth across multiple regions.

DPM Metals has reported record financial results for 2025, driven by strong free cash flow and earnings, while advancing key projects and maintaining a low-cost production profile. The company’s three-year outlook highlights significant production growth and disciplined capital management.